Regend Therapeutics   Report issue

For profit Phase 2
Founded: Suzhou China (2015)

Organization Overview

First Clinical Trial
2016
NCT02722642
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Regend Therapeutics | Regend Therapeutics Co.Ltd